As a leading innovation-driven corporation, Lilly is developing a growing portfolio of first-in-class and best-in-class pharmaceutical products to meet some of the world's most urgent medical needs.
Here is a listing of our current marketed portfolio of medicines. For full prescribing information, please click on the respective product website links.
Cancer
Cardiology
Diabetes
- Byetta® (exenatide) injection** **
- Glucagon™ (glucagon for injection [rDNA origin])
- Humulin® (human insulin [rDNA origin])
- Humalog® (insulin lispro injection [rDNA origin])
- Humalog® Mix75/25™ (75% Insulin lispro protamine suspension, 25% insulin lispro injection [rDNA origin])
- Humalog® Mix50/50™ (50% Insulin lispro protamine suspension, 50% insulin lispro injection [rDNA origin])
- Humulin® Pen (human insulin [rDNA origin]) and Humalog® Pen (insulin lispro [rDNA origin])
Diabetic Peripheral Neuropathic Pain (DPNP)
Erectile Dysfunction
Fibromyalgia
Growth Disorders
Neuroscience
- Cymbalta® (duloxetine hydrochloride)
- Prozac® (fluoxetine hydrochloride)
- Strattera®(atomoxetine hydrochloride)
- Symbyax® (olanzapine and fluoxetine hydrochloride)
- Zyprexa® (olanzapine)
Osteoporosis
Sepsis
* ReoPro is a registered trademark of Centocor Inc.
** Byetta is a registered trademark of Amylin Pharmaceuticals, Inc.
Patient Assistance Programs
Some patients need help affording medicines. Lilly has several programs that may help.
Learn More
